A NOVEL SCREEN FOR ANTIFUNGALS THAT TARGET CHITOSAN BIOSYNTHESIS
针对壳聚糖生物合成的新型抗真菌药物筛选
基本信息
- 批准号:8545318
- 负责人:
- 金额:$ 39.65万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2012
- 资助国家:美国
- 起止时间:2012-09-24 至 2014-08-31
- 项目状态:已结题
- 来源:
- 关键词:Acquired Immunodeficiency SyndromeAction PotentialsAdverse effectsAnabolismAntifungal AgentsAntifungal TherapyBindingBiological AssayCell LineCell WallCellsCessation of lifeChitinChitin SynthaseChitosanComplexCountryCryptococcusCryptococcus neoformansCryptococcus neoformans infectionDataDeacetylationDevelopmentDiseaseEnsureEnzyme InhibitionEnzymesEquipmentFamilyFutureGeneticGrowthHomologous GeneHumanImmunocompromised HostIndividualInfectionInstitutesLife Cycle StagesMammalsMethodsMycosesNIH Program AnnouncementsNational Institute of Allergy and Infectious DiseaseNew AgentsOrgan TransplantationOrganellesPhenotypePolysaccharidesPreparationProcessProductionProteinsPublishingReagentRelapseRiskScreening procedureSpecificityStaining methodStainsSystemTemperatureTestingTherapeuticTimeToxic effectUnited States National Institutes of HealthVirulenceassay developmentbasecalcofluor whitechemotherapycytotoxicdesignfungushigh throughput screeninginhibitor/antagonistinterestkillingsmeetingsminiaturizemouse modelnovelnovel strategiespatient populationpreventresponse
项目摘要
DESCRIPTION (provided by applicant): Cryptococcus neoformans is a pathogenic fungus that is found world-wide and causes meningioencephalitis, particularly in immunocompromised individuals. It is invariably fatal unless treated, and the current antifungals are inadequate to effectively cure this disease, due to inherent toxicities or the inability to kill the fungus and prevent relapse. Recent studies have indicated that there are over 1,000,000 new cases of cryptococcosis in the world each year, which results in over 600,000 deaths. New agents to treat Cryptococcus are needed. We have shown that chitosan, the deacetylated form of chitin, is a critical component of the Cryptococcal cell wall and is absolutely required for virulence using a
mouse model of cryptococcosis. Our studies have further identified the key enzymes required for chitosan production. This assay development proposal is based on our findings that deletion strains that eliminate chitosan formation share a common set of phenotypes, termed "chitosan deficiency", which we propose to exploit to identify novel antifungal drugs. The key phenotypes of chitosan deficiency can be combined for the development of robust, miniaturized high throughput screening (HTS) assays. These are reduced growth at elevated temperatures and changes in staining of the cell wall. The proposed assay development strategy is supported by the many genetic deletion strains which we have derived that will enable chitosan deficiency hit selection and profiling. We also show preliminary capabilities to characterize mechanism of action of selected hits through direct enzyme inhibition. The chitin that is deacetylated is primarily generated through the action of a single chitin synthase and a specific chitin synthase regulator, even though Cryptococcus encodes seven other synthases and two other synthase regulators. The deacetylation is also dependent upon a family of three chitin deacetylases that we hypothesize to act in concert with the synthase/regulator. This application is a proposal to develop primary assays that will be suitable for a high-throughput screen (HTS) to identify candidate compounds that will inhibit the biosynthesis of chitosan in cryptococcus. We will also develop secondary screens to rule out non-specific cytotoxic compounds and we present preliminary enzyme assay data that supports our ability to develop the necessary tertiary assays to characterize and validate the screening hits. Our lab has the needed equipment and space to develop the reagents, cell lines and assays outlined in this proposal. We also have considerable industrial HTS expertise in the lab that will ensure that the assays and strategies developed through this proposal will successfully meet the standards of any HTS facility that would implement them. This proposal represents a novel approach to antifungal inhibitor discovery and targets proteins that have no homologies in humans or other mammals.
描述(由申请方提供):新型隐球菌是一种致病真菌,在世界范围内发现,可引起脑膜脑炎,尤其是在免疫功能低下的个体中。除非治疗,否则它总是致命的,并且由于固有的毒性或不能杀死真菌并防止复发,目前的抗真菌药物不足以有效治愈这种疾病。最近的研究表明,全世界每年有超过1,000,000例新的隐球菌病病例,导致超过600,000人死亡。需要新的药物来治疗隐球菌。我们已经证明,壳聚糖,脱乙酰化形式的几丁质,是一个关键组成部分的隐球菌细胞壁,是绝对需要的毒力,使用
隐球菌病小鼠模型。我们的研究进一步确定了壳聚糖生产所需的关键酶。该测定开发建议基于我们的发现,即消除壳聚糖形成的缺失菌株具有一组共同的表型,称为“壳聚糖缺乏症”,我们建议利用该表型来鉴定新型抗真菌药物。壳聚糖缺乏症的关键表型可以组合用于开发稳健的小型化高通量筛选(HTS)测定。这些是在升高的温度下生长减少和细胞壁染色的变化。所提出的测定开发策略得到了我们所衍生的许多遗传缺失菌株的支持,这些菌株将能够进行壳聚糖缺陷命中选择和分析。我们还展示了通过直接酶抑制来表征选定命中的作用机制的初步能力。脱乙酰化的几丁质主要通过单一几丁质合成酶和特定几丁质合成酶调节剂的作用产生,尽管隐球菌编码七种其他几丁质酶和两种其他合成酶调节剂。脱乙酰化也依赖于一个家庭的三个几丁质脱乙酰酶,我们假设采取行动,在演唱会与合酶/调节器。本申请是一个建议,以开发初级检测,将适合于高通量筛选(HTS),以确定候选化合物,将抑制壳聚糖在隐球菌的生物合成。我们还将开发二次筛选以排除非特异性细胞毒性化合物,并提供初步的酶测定数据,以支持我们开发必要的三级测定以表征和验证筛选命中的能力。我们的实验室拥有所需的设备和空间来开发本提案中概述的试剂,细胞系和测定。我们在实验室中还拥有相当多的工业HTS专业知识,这将确保通过本提案开发的检测和策略将成功满足任何HTS设施的标准。这一提议代表了一种新的方法,以抗真菌抑制剂的发现和目标蛋白质,在人类或其他哺乳动物中没有同源性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Jennifer K. Lodge其他文献
Immunological correlates of protection mediated by a whole organism, emCryptococcus neoformans/em, vaccine deficient in chitosan
壳聚糖缺陷的新型隐球菌全菌疫苗介导的保护性免疫相关因素
- DOI:
10.1128/mbio.01746-24 - 发表时间:
2024-07-26 - 期刊:
- 影响因子:4.700
- 作者:
Charles A. Specht;Ruiying Wang;Lorena V. N. Oliveira;Maureen M. Hester;Christina Gomez;Zhongming Mou;Diana Carlson;Chrono K. Lee;Camaron R. Hole;Woei C. Lam;Rajendra Upadhya;Jennifer K. Lodge;Stuart M. Levitz - 通讯作者:
Stuart M. Levitz
Jennifer K. Lodge的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Jennifer K. Lodge', 18)}}的其他基金
2014 Cellular and Molecular Fungal Biology Gordon Research Conference
2014年细胞与分子真菌生物学戈登研究会议
- 批准号:
8718564 - 财政年份:2014
- 资助金额:
$ 39.65万 - 项目类别:
Identification of Antifungal Targets Using Proteomics
使用蛋白质组学鉴定抗真菌靶点
- 批准号:
6861054 - 财政年份:2003
- 资助金额:
$ 39.65万 - 项目类别:
Identification of Antifungal Targets Using Proteomics
使用蛋白质组学鉴定抗真菌靶点
- 批准号:
6701783 - 财政年份:2003
- 资助金额:
$ 39.65万 - 项目类别:
Identification of Antifungal Targets Using Proteomics
使用蛋白质组学鉴定抗真菌靶点
- 批准号:
6656801 - 财政年份:2003
- 资助金额:
$ 39.65万 - 项目类别:
相似海外基金
Kilohertz volumetric imaging of neuronal action potentials in awake behaving mice
清醒行为小鼠神经元动作电位的千赫兹体积成像
- 批准号:
10515267 - 财政年份:2022
- 资助金额:
$ 39.65万 - 项目类别:
Signal processing in horizontal cells of the mammalian retina – coding of visual information by calcium and sodium action potentials
哺乳动物视网膜水平细胞的信号处理 â 通过钙和钠动作电位编码视觉信息
- 批准号:
422915148 - 财政年份:2019
- 资助金额:
$ 39.65万 - 项目类别:
Research Grants
CAREER: Resolving action potentials and high-density neural signals from the surface of the brain
职业:解析来自大脑表面的动作电位和高密度神经信号
- 批准号:
1752274 - 财政年份:2018
- 资助金额:
$ 39.65万 - 项目类别:
Continuing Grant
Development of Nanosheet-Based Wireless Probes for Multi-Simultaneous Monitoring of Action Potentials and Neurotransmitters
开发基于纳米片的无线探针,用于同时监测动作电位和神经递质
- 批准号:
18H03539 - 财政年份:2018
- 资助金额:
$ 39.65万 - 项目类别:
Grant-in-Aid for Scientific Research (B)
Population Imaging of Action Potentials by Novel Two-Photon Microscopes and Genetically Encoded Voltage Indicators
通过新型双光子显微镜和基因编码电压指示器对动作电位进行群体成像
- 批准号:
9588470 - 财政年份:2018
- 资助金额:
$ 39.65万 - 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
- 批准号:
10009724 - 财政年份:2018
- 资助金额:
$ 39.65万 - 项目类别:
Enhanced quantitative imaging of compound action potentials in multi-fascicular peripheral nerve with fast neural Electrical Impedance Tomography enabled by 3D multi-plane softening bioelectronics
通过 3D 多平面软化生物电子学实现快速神经电阻抗断层扫描,增强多束周围神经复合动作电位的定量成像
- 批准号:
10467225 - 财政年份:2018
- 资助金额:
$ 39.65万 - 项目类别:
Fast high-resolution deep photoacoustic tomography of action potentials in brains
大脑动作电位的快速高分辨率深度光声断层扫描
- 批准号:
9423398 - 财政年份:2017
- 资助金额:
$ 39.65万 - 项目类别:
NeuroGrid: a scalable system for large-scale recording of action potentials from the brain surface
NeuroGrid:用于大规模记录大脑表面动作电位的可扩展系统
- 批准号:
9357409 - 财政年份:2016
- 资助金额:
$ 39.65万 - 项目类别:
Noval regulatory mechanisms of axonal action potentials
轴突动作电位的新调节机制
- 批准号:
16K07006 - 财政年份:2016
- 资助金额:
$ 39.65万 - 项目类别:
Grant-in-Aid for Scientific Research (C)